Medication Adherence to Tyrosine Kinase Inhibitors: 2-Year Analysis of Medication Adherence to Imatinib Treatment for Chronic Myeloid Leukemia and Correlation with the Depth of Molecular Response
| Autor: | Paolo Bartolomeo, Antonio Vetro, Roberto Di Lorenzo, Ruggero Lasala, Alberto Costantini, Fiorenzo Santoleri, Gaetano La Barba, Elena Ranucci |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
medicine.drug_class bcr-abl Antineoplastic Agents Pharmacology 030226 pharmacology & pharmacy Piperazines Tyrosine-kinase inhibitor Medication Adherence 03 medical and health sciences European LeukemiaNet 0302 clinical medicine Internal medicine medicine Humans Chronic Protein Kinase Inhibitors Retrospective Studies Prescribed daily dose Leukemia Hematology business.industry Chronic myeloid leukemia Fusion Proteins Myeloid leukemia Retrospective cohort study Imatinib General Medicine Protein-Tyrosine Kinases medicine.disease Medication adherence Received daily dose Benzamides Fusion Proteins bcr-abl Leukemia Myelogenous Chronic BCR-ABL Positive Pyrimidines Treatment Outcome Imatinib Mesylate Imatinib mesylate 030220 oncology & carcinogenesis BCR-ABL Positive business Myelogenous medicine.drug |
| Zdroj: | Acta Haematologica. 136:45-51 |
| ISSN: | 1421-9662 0001-5792 |
| DOI: | 10.1159/000444626 |
| Popis: | Objective: Adherence to tyrosine kinase inhibitor treatment is a significant factor in the achievement of a good clinical response in chronic myeloid leukemia (CML). The aim of this retrospective study is to investigate 1- and 2-year medication adherence to imatinib treatment, linking adherence rates with the clinical outcome, in accordance with European LeukemiaNet Recommendations for the management of CML. We have tried to find a cutoff value for adherence in order to achieve a good clinical outcome. Methods: The method used to calculate medication adherence was the ratio between the received and the prescribed daily dose. Results: We observed the levels of mean adherence for each of the following response groups (in years 1 and 2, respectively): complete response (0.96, 0.95), MR4.5 (1.00, -), MR4 (0.93, 0.91), major molecular responses (0.96, 0.97), warning (0.91, 0.89) and failure (0.79, 0.84). Conclusion: Results show that the higher the adherence, the lower the level of BCR-ABL1. Furthermore, using cutoffs ≥0.9, outcomes were significantly improved compared to those with cutoffs |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|